Garson J A, Pemberton L F, Sheppard P W, Varndell I M, Coakham H B, Kemshead J T
Imperial Cancer Research Fund Oncology Laboratory, Institute of Child Health, London, UK.
Br J Cancer. 1989 Jun;59(6):889-94. doi: 10.1038/bjc.1989.188.
Although medulloblastoma and neuroblastoma share many common biological, histological and immunological features, the frequency of N-myc amplification differs markedly between the two tumours. In this study, Southern blot analysis revealed that the N-myc gene was not amplified in any of the nine medulloblastoma samples analysed. In contrast, over-expression of the gene was found in six of 11 samples as determined by immunocytochemistry and/or Western blot analysis, using an antiserum raised against a synthetic peptide representing a sequence unique to the N-myc gene product. The specificity of this reagent was demonstrated by studies on a variety of cell lines expressing N-myc and/or c-myc oncoproteins. Of the 12 medulloblastoma samples collected over a two-year period and analysed in the course of this project, a trend towards longer disease-free survival was noted in the patients having low levels of the N-myc protein in their tumour.
虽然髓母细胞瘤和神经母细胞瘤具有许多共同的生物学、组织学和免疫学特征,但两种肿瘤中N-myc基因扩增的频率明显不同。在本研究中,Southern印迹分析显示,在所分析的9个髓母细胞瘤样本中,N-myc基因均未扩增。相反,使用针对代表N-myc基因产物独特序列的合成肽产生的抗血清,通过免疫细胞化学和/或Western印迹分析确定,在11个样本中的6个样本中发现该基因过表达。通过对多种表达N-myc和/或c-myc癌蛋白的细胞系进行研究,证明了该试剂的特异性。在本项目过程中收集并分析的12个髓母细胞瘤样本中,在肿瘤中N-myc蛋白水平较低的患者中,观察到无病生存期延长的趋势。